Is genotype 3 of the hepatitis C virus the new villain?
- PMID: 24155107
- DOI: 10.1002/hep.26905
Is genotype 3 of the hepatitis C virus the new villain?
Abstract
Genotype 3 of the hepatitis C virus (HCV) has been long considered an easy-to-treat infection, with higher cure rates (∼70%) than other viral genotypes with the standard combination of pegylated interferon-α and ribavirin. However, the relative insensitivity of this genotype to most protease inhibitors and the recent unexpected data on decreased effectiveness of sofosbuvir have raised questions on how to achieve universal cure, a goal that seems reasonable for other genotypes. In addition, increasing clinical and experimental data show that HCV genotype 3 may be associated not only with severe steatosis, but also with accelerated fibrosis progression rate and increased oncogenesis.
Conclusion: Currently available data suggest that we should increase our efforts to understand the virology and pathogenesis of HCV genotype 3, aiming at better and more potent, genotype-targeted treatments.
© 2014 by the American Association for the Study of Liver Diseases.
Similar articles
-
Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.Intervirology. 2006;49(1-2):96-8. doi: 10.1159/000087270. Intervirology. 2006. PMID: 16166796 Clinical Trial.
-
[Hepatitis C virus: 25 years-old, the end?].Med Sci (Paris). 2013 Nov;29(11):998-1003. doi: 10.1051/medsci/20132911016. Epub 2013 Nov 20. Med Sci (Paris). 2013. PMID: 24280503 Review. French.
-
High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease.Ital J Gastroenterol. 1996 Oct-Nov;28(8):452-6. Ital J Gastroenterol. 1996. PMID: 9032588
-
[Treatment of hepatitis C: current status and perspectives].Rev Prat. 2014 May;64(5):605-12. Rev Prat. 2014. PMID: 24923038 French.
-
Management of hepatitis C virus genotype 4.J Gastroenterol Hepatol. 2004 Nov;19(11):1233-9. doi: 10.1111/j.1440-1746.2003.03325.x. J Gastroenterol Hepatol. 2004. PMID: 15482528 Review.
Cited by
-
Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Hepat Med. 2015 Apr 16;7:11-20. doi: 10.2147/HMER.S79584. eCollection 2015. Hepat Med. 2015. PMID: 25926761 Free PMC article. Review.
-
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection.Acta Biomed. 2018 Oct 8;89(3):321-331. doi: 10.23750/abm.v89i3.7718. Acta Biomed. 2018. PMID: 30333452 Free PMC article. Review.
-
Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis.Front Med (Lausanne). 2022 May 18;9:802686. doi: 10.3389/fmed.2022.802686. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35665327 Free PMC article.
-
The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.Gut. 2016 Jan;65(1):112-23. doi: 10.1136/gutjnl-2014-308724. Epub 2015 Jun 19. Gut. 2016. PMID: 26092843 Free PMC article.
-
Hepatitis C virus-induced hepatocellular carcinoma.Clin Mol Hepatol. 2015 Jun;21(2):105-14. doi: 10.3350/cmh.2015.21.2.105. Epub 2015 Jun 26. Clin Mol Hepatol. 2015. PMID: 26157746 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical